Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Type D personality

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6 result(s) found for: Type D personality. Displaying page 1 of 1.
    EudraCT Number: 2020-003469-20 Sponsor Protocol Number: CL07-ORY-2001 Start Date*: 2020-11-06
    Sponsor Name:Oryzon Genomics S.A.
    Full Title: A double blind, randomized, placebo-controlled, adaptive 14-week Phase IIb trial to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population (POR...
    Medical condition: Borderline Personality Disorder (BPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10006034 Borderline personality disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-003136-23 Sponsor Protocol Number: CRO1990 Start Date*: 2012-11-27
    Sponsor Name:Imperial College London
    Full Title: Lamotrigine And Borderline Personality Disorder: Investigating Long-Term Effectiveness
    Medical condition: Borderline Personality Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10042033 Stevens-Johnson syndrome PT
    14.1 10029205 - Nervous system disorders 10019211 Headache PT
    15.0 100000004856 10028821 Nausea with vomiting LLT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10040913 Skin rash LLT
    14.1 10029205 - Nervous system disorders 10024264 Lethargy PT
    14.1 10029205 - Nervous system disorders 10013649 Drowsiness LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002819-28 Sponsor Protocol Number: OCDDCS001 Start Date*: 2012-04-12
    Sponsor Name:Stockholms Läns Landsting
    Full Title: Internet-based cognitive behavior therapy in combination with D-Cycloserine for Obsessive Compulsive Disorder: A double blinded randomized controlled trial
    Medical condition: Obsessive Compulsive disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10029898 Obsessive-compulsive disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000256-33 Sponsor Protocol Number: Ra-P-OCD-01 Start Date*: 2019-06-27
    Sponsor Name:Uppsala University Hospital
    Full Title: A randomized, double-blinded, placebo-controlled study of Rituximab in patients with Psychosis and/or Obsessive Compulsive Disorder, with an indication of immune system involvement
    Medical condition: Obsessive-compulsive disorder (OCD) or Obsessive-compulsive behaviour (OCB) or psychotic disorder (PD) in which there is an indication of immune system involvement.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10029898 Obsessive-compulsive disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-004037-18 Sponsor Protocol Number: 42603ATT3004 Start Date*: 2006-03-10
    Sponsor Name:Janssen-Cilag Medical Affairs EMEA
    Full Title: An Open Label, Multicentre Study to Evaluate the Long Term Safety of Prolonged Release (PR) OROS Methylphenidate (18, 36, 54, 72 and 90 mg/day) in Adults with Attention Deficit/Hyperactivity Disor...
    Medical condition: Attention Deficit-Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    7.1 10003735 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001637-27 Sponsor Protocol Number: LQD Start Date*: 2016-09-20
    Sponsor Name:South London and Maudsley NHS Foundation Trust [...]
    1. South London and Maudsley NHS Foundation Trust
    2. King's College London
    Full Title: A randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression.
    Medical condition: Treatment resistant major depressive disorder (single episode or recurrent). Treatment resistant depression, defined as failure to respond to two or more adequate doses of antidepressant in the cur...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10067373 Depression perimenopausal LLT
    21.1 10037175 - Psychiatric disorders 10066555 Chronic depression LLT
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    20.0 10037175 - Psychiatric disorders 10012391 Depression postpartum (excl psychosis) LLT
    20.0 10022117 - Injury, poisoning and procedural complications 10012390 Depression postoperative PT
    20.0 10037175 - Psychiatric disorders 10012386 Depression mental LLT
    21.1 10037175 - Psychiatric disorders 10066530 Acute depression LLT
    20.0 10037175 - Psychiatric disorders 10012389 Depression postmenopausal LLT
    20.0 10037175 - Psychiatric disorders 10012387 Depression NOS LLT
    20.0 10037175 - Psychiatric disorders 10012378 Depression PT
    21.1 10037175 - Psychiatric disorders 10045543 Unipolar depression LLT
    21.1 10037175 - Psychiatric disorders 10037998 Reactive depression LLT
    21.1 10037175 - Psychiatric disorders 10042457 Suicidal depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 22 21:51:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA